STOCKWATCH

Glenmark Pharma Expands Cardiometabolic Portfolio with Empagliflozin Launch in India

Glenmark Pharmaceuticals Ltd. has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India under the brand names Glempa, Glempa-L, and Glempa-M. These medications are designed to improve glycemic control in adults with T2DM while also reducing cardiovascular outcomes in T2DM patients with CV risk. Empagliflozin is a globally established treatment for HF, T2DM, and T2DM with established CVD, offering multiple benefits like cardiovascular and renal safety. The EMPA-REG clinical trial demonstrated a 14% reduction in major cardiovascular events, positioning Empagliflozin as a significant advancement in T2DM patients with high CV risks.

• Glenmark Pharma launches Empagliflozin in India under the brand names Glempa, Glempa-L, and Glempa-M
• Empagliflozin is a globally established treatment for HF, T2DM, and T2DM with established CVD
• Empagliflozin offers multiple benefits like cardiovascular and renal safety
• EMPA-REG clinical trial demonstrated a 14% reduction in major cardiovascular events
• New treatment options cater to diverse patient needs and improve health outcomes for millions of patients across India